Health productsUpdated Jan 3, 2026COPAXONEOfficial source

    COPAXONE recall in Canada: risk of anaphylactic reactions

    Share:

    In plain language

    This recall involves COPAXONE (glatiramer acetate) 20 mg/mL and 40 mg/mL pre-filled syringes and pens sold in Canada. It's being recalled because it can cause anaphylactic reactions, which may be fatal and can occur at any time during treatment. Stop using the product and follow the return/repair steps in the official notice.

    What to do

    • Stop using the product immediately.
    • Seek immediate emergency medical care if an anaphylactic reaction occurs.
    • Do not restart COPAXONE if you have experienced anaphylaxis unless another clear cause is identified.
    • Contact a healthcare professional if you have any immediate post-injection reaction symptoms.

    Get alerts for recalls like this

    Get email alerts when new recalls affect products in this category.

    Categories (optional)

    No spam. Unsubscribe anytime. We only email when there's a relevant recall.

    Affected products

    • COPAXONE (glatiramer acetate) 20 mg/mL, single-use pre-filled syringes for subcutaneous injection

    • COPAXONE (glatiramer acetate) 40 mg/mL, single-use pre-filled syringes for subcutaneous injection

    • COPAXONE (glatiramer acetate) 40 mg/mL, single-use pre-filled pens for subcutaneous injection

    Why this matters

    Anaphylactic reaction risk

    Do I have this product?

    This recall only applies to specific products. Follow the steps below to check.

    1. 1

      Check the product name

      Make sure your product name matches one of the affected products listed above.

    If your product matches one or more of the details above, it may be affected by this recall.

    If your product does not match these details, it is not affected by this recall.

    When in doubt, always check the official notice.

    Want alerts if similar products are recalled in Canada?

    Frequently Asked Questions

    Why was this product recalled?

    Anaphylactic reaction risk

    What should consumers do?

    Stop using the product immediately. Seek immediate emergency medical care if an anaphylactic reaction occurs. Do not restart COPAXONE if you have experienced anaphylaxis unless another clear cause is identified. Contact a healthcare professional if you have any immediate post-injection reaction symptoms.

    Where was the product sold?

    This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.

    Is there a health risk?

    Yes, there may be a health risk. Anaphylactic reaction risk

    When was this product recalled?

    This product was recalled on August 21, 2025.

    Is the COPAXONE brand affected by this recall?

    Yes, COPAXONE products are affected by this recall. This recall involves COPAXONE (glatiramer acetate) 20 mg/mL and 40 mg/mL pre-filled syringes and pens sold in Canada. It's being recalled because it can cause anaphylactic reactions, which may be fatal and can occur at any time during treatment. Stop using the product and follow the return/repair steps in the official notice.